Annie McGuire
Personalreferent bei VERACYTE, INC.
Vermögen: 255 305 $ am 30.04.2024
Profil
Annie McGuire is currently the Chief People Officer, EVP & General Counsel at Veracyte, Inc. Previously, she worked as the Senior Corporate Counsel at Amgen, Inc., Vice President-Legal at MyoKardia, Inc., and Secretary & General Counsel at Rakuten Medical, Inc. She obtained her undergraduate degree from Pace University and her graduate degree from New York Law School.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
VERACYTE INC
0,02% | 31.03.2024 | 13 106 ( 0,02% ) | 255 305 $ | 30.04.2024 |
Aktive Positionen von Annie McGuire
| Unternehmen | Position | Beginn |
|---|---|---|
| VERACYTE, INC. | Personalreferent | - |
Ehemalige bekannte Positionen von Annie McGuire
| Unternehmen | Position | Ende |
|---|---|---|
| MYOKARDIA, INC. | Corporate Officer/Principal | - |
| AMGEN INC. | Corporate Officer/Principal | - |
Rakuten Medical, Inc.
 Rakuten Medical, Inc. Miscellaneous Commercial ServicesCommercial Services Rakuten Medical, Inc. operates as a clinical stage biotechnology company which develops tumor-targeted precision therapies. It develops new anticancer therapies based on the photoimmunotherapy platform. The company was founded in 2010 and is headquartered in San Diego, CA. | General Counsel | - |
Ausbildung von Annie McGuire
| New York Law School | Graduate Degree |
| Pace University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| VERACYTE, INC. | Health Technology |
| AMGEN INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Rakuten Medical, Inc.
Rakuten Medical, Inc. Miscellaneous Commercial ServicesCommercial Services Rakuten Medical, Inc. operates as a clinical stage biotechnology company which develops tumor-targeted precision therapies. It develops new anticancer therapies based on the photoimmunotherapy platform. The company was founded in 2010 and is headquartered in San Diego, CA. | Commercial Services |
MyoKardia, Inc.
 MyoKardia, Inc. Pharmaceuticals: MajorHealth Technology MyoKardia, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, commercialization, and development of therapies for the treatment of cardiovascular diseases. Its lead therapeutic candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin being developed for the treatment of hypertrophic cardiomyopathy (HCM). The company was founded by James A. Spudich, Jonathan G. Seidman, Christine Seidman, and Leslie Leinwand on June 8, 2012 and is headquartered in South San Francisco, CA. | Health Technology |
